Health data company Truveta said Monday it’s partnering with health systems and drugmakers to launch the Truveta Genome Project, a database of genetic data that is expected to accelerate personalized medicine and help discover new drugs.
Truveta plans to use leftover biospecimens from patients — after they consent — receiving routine health care at participating health systems to create the database. The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies.
Pharmaceutical company Regeneron has invested $119.5 million in Truveta’s project, and its laboratory subsidiary the Regeneron Genetics Center will sequence the exomes of the first 10 million volunteers for the program. DNA sequencer manufacturer Illumina has also invested $20 million in the project, which builds on a 2021 investment and partnership from Microsoft, which will provide the cloud infrastructure for the project.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in